Modality
Degrader
MOA
FGFRi
Target
B7-H3
Pathway
Ferroptosis
RCC
Development Pipeline
Preclinical
~Apr 2021
→ ~Jul 2022
Phase 1
~Oct 2022
→ ~Jan 2024
Phase 2
~Apr 2024
→ ~Jul 2025
Phase 3
Oct 2025
→ Jan 2029
Phase 3Current
NCT07793889
975 pts·RCC
2025-10→2029-01·Not yet recruiting
975 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-192.8y awayPh3 Readout· RCC
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P3
Not yet…
Catalysts
Ph3 Readout
2029-01-19 · 2.8y away
RCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07793889 | Phase 3 | RCC | Not yet recr... | 975 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 |